↓ Skip to main content

Dove Medical Press

Article Metrics

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis

Overview of attention for article published in Neuropsychiatric Disease and Treatment, September 2011
Altmetric Badge

Mentioned by

twitter
1 tweeter

Readers on

mendeley
29 Mendeley
Title
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
Published in
Neuropsychiatric Disease and Treatment, September 2011
DOI 10.2147/ndt.s10481
Pubmed ID
Authors

Bernd Kieseier, Warnke, Stuve, Peter Hartung, Fogdell-Hahn

Abstract

This review summarizes Phase III clinical trial data available for fingolimod. The main purpose is to evaluate the benefit-risk profile of fingolimod, the first oral compound available for treatment of multiple sclerosis (MS) and just recently approved by the European authorities. The authors place this evaluation in the context of the known safety and efficacy profile of established compounds for therapy of MS to outline the current and future potential of fingolimod. The authors conclude that only long-term safety data from post-marketing surveillance plans, together with additional head-to-head studies, would allow evidence-based treatment decisions. Furthermore, risk-profile analyses including patient history, exposure data to certain pathogens, and genetic analyses may potentially help to choose the right drug for individual patients in the future. Until these approaches toward an individualized medicine have been validated, treatment decisions for one or the other compound will have to be based partly on class IV evidence. Therefore, a close dialog with the well-informed patient, secured by effective risk mitigation plans, is required to choose the compound.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 29 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 3%
Professor > Associate Professor 1 3%
Unknown 27 93%
Readers by discipline Count As %
Medicine and Dentistry 1 3%
Unknown 28 97%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 September 2011.
All research outputs
#10,016,513
of 12,517,383 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,644
of 2,120 outputs
Outputs of similar age
#84,862
of 119,593 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#24
of 33 outputs
Altmetric has tracked 12,517,383 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,120 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.6. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 119,593 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.